Neuronetics to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum

Neuronetics, Inc. (NASDAQ: STIM) announced its management team will present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020, at 12:30 PM ET.

Rhea-AI Summary

Neuronetics, Inc. (NASDAQ: STIM) announced its management team will present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020, at 12:30 PM ET. A live audio webcast will be accessible on the company's investor relations page, with a replay available for 90 days. Neuronetics focuses on improving quality of life for psychiatric disorder patients through its NeuroStar® Advanced Therapy System, an FDA-cleared, non-invasive treatment for major depressive disorder. The system is also recognized under Japan's national health insurance.

Argus Session date unavailable

+6.89% session move Open Argus

Details

News Market Reaction – STIM

The recorded move for STIM in the trading session of this news was +6.89%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MALVERN, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that the management team will present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020 at 12:30pm ET.

A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.neuronetics.com. A replay of the webcast will be archived on the website for approximately 90 days.

About Neuronetics

Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Our first commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. NeuroStar is also available in other parts of the world, including Japan, where it is listed under Japan’s national health insurance. Additional information can be found at www.neuronetics.com.

Investor Contact:

Mark R. Klausner
Westwicke Partners
443-213-0501
ir@neuronetics.com

Media Contact:

Chelsey Manko
Vault Communications
610-455-2778
cmanko@vaultcommunications.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Neuronetics present at the Canaccord Genuity Virtual MedTech Forum?

Neuronetics will present on November 19, 2020, at 12:30 PM ET.

How can I access the Neuronetics presentation webcast?

The presentation will be available on Neuronetics' investor relations page, and a replay will be archived for 90 days.

What is the NeuroStar® Advanced Therapy System?

It is a non-invasive treatment using transcranial magnetic stimulation for patients with major depressive disorder.

Is the NeuroStar system FDA approved?

Yes, it is FDA-cleared for adult patients who have not improved with prior antidepressant medication.

In which countries is NeuroStar available?

NeuroStar is available in the U.S. and Japan, where it is listed under national health insurance.